A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer by Hoff, P M et al.
A phase II study of UFT with leucovorin administered as a
twice daily schedule in the treatment of patients with
metastatic colorectal cancer
PM Hoff*,1,2,3, S Kopetz
1, MB Thomas
1, A Langleben
4, D Rinaldi
5, L Anthony
6, RA Wolff
1, Y Lassere
1 and
JL Abbruzzese
1
1Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA;
2Discipline of
Gastrointestinal Surgery, University of Sao Paulo, Sao Paulo, Brazil;
3Hospital Sirio Libanes, Sao Paulo, Brazil;
4Department of Oncology, Royal Victoria
Hospital, Montreal, Quebec, Canada;
5Louisiana Oncology Associates, Lafayette, Louisiana 70506, USA;
6Louisiana State University Health Sciences
Center, New Orleans, Louisiana 70112, USA
Prolonged infusions have been shown to be safer and potentially more effective than bolus regimens of 5-fluorouracil (5-FU) as
treatment for metastatic colorectal cancer (mCRC). However, infusional 5-FU requires central venous access and costly infusion
pumps. Oral fluoropyrimidines enable longer exposures to 5-FU with increased convenience. Tegafur–uracil (UFT) with leucovorin
(LV) given thrice daily has improved safety plus comparable survival and response rates to bolus 5-FU/LV. We conducted a phase II
clinical study in 98 patients with mCRC to evaluate if UFT with LV given twice daily provided comparable time to progression (TTP),
efficacy and tolerability to that reported for thrice daily in two phase III clinical studies. Secondary objectives included overall response
rate (ORR) and overall survival (OS). Median TTP was 3.8 months, when compared with 3.5 months for thrice daily. The ORR (11%)
and median OS (12.8 months) with twice daily administration were similar to that of thrice daily administration (12% and 12.4
months). The incidence of grade 3/4 treatment-related diarrhoea was 30% on the twice daily and 21% on the thrice daily schedule.
These results suggest that twice daily administration has similar efficacy and tolerability to thrice daily administration and is an
acceptable alternative for patients who would benefit from UFT with LV therapy.
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Despite the recent advances in treatment, colorectal cancer (CRC)
remains the second leading cause of cancer death in the United
States (Jemal et al, 2007). Most CRCs are adenocarcinomas, and
the primary method of treatment is surgery, which can result in
cure, depending on the stage of the disease at the time of diagnosis.
Metastatic CRC (mCRC) is usually treated with 5-fluorouracil
(5-FU)-based chemotherapy, either 5-FU alone or in combination
with modulators and other cytotoxic agents, such as irinotecan and
oxaliplatin (Kopetz and Hoff, 2005).
A meta-analysis of randomised clinical studies comparing 5-FU
regimens for the treatment of mCRC showed that continuous
infusion was superior to bolus administration in terms of tumour
response (22 vs 14%) and median survival (12.1 vs 11.3 months)
(Meta-Analysis Group in Cancer, 1998). After entering the
circulation, most of the infused 5-FU is rapidly converted to
inactive metabolites by dihydropyrimidine dehydrogenase (DPD)
(Diasio, 2001). The remainder is converted to fluorouridine
monophosphate, which is subsequently converted to fluorouridine
diphosphate and then to either fluorouridine triphosphate (FUTP)
or fluorodeoxyuridine monophosphate (FdUMP) (Schilsky, 1992).
The mechanisms of 5-FU cytotoxicity include the inhibition of
DNA synthesis through the inhibition of thymidylate synthase (TS)
by FdUMP (Peters et al, 1989) and the inhibition of RNA synthesis
when FUTP is incorporated into RNA (Daher et al, 1990; Hoff et al,
1999a). The side effects of bolus 5-FU and the inconvenience of
prolonged infusions have led investigators to search for delivery
alternatives for 5-FU, including such oral prodrugs as tegafur,
tegafur–uracil (UFT) and capecitabine (Hoff et al, 1999a).
Tegafur is a fluorinated pyrimidine first synthesised by Hiller
et al (1967). After showing significant neurotoxicity when
administered intravenously (Buroker et al, 1979), it was developed
in Japan as an oral formulation. It can be orally administered
because it is absorbed as an intact molecule and is not metabolised
by DPD in the gastrointestinal tract. Once tegafur is metabolised to
5-FU, mostly in the liver, it enters the same pathway as intravenous
(i.v.) 5-FU and has the same cytotoxic mechanism of action (Hoff
et al, 1999a).
Tegafur–uracil, a combination of tegafur and uracil in a 1:4
molar ratio, is a further development of the concept. Uracil is
naturally metabolised by DPD and competes with 5-FU for the
enzyme when the two are administered together, resulting in a
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ssignificantly prolonged half-life for 5-FU, mimicking continuous
infusion (Hoff et al, 1998). Leucovorin (LV), also known as folinic
acid, is a tetrahydrofolic acid derivative that can enhance the
therapeutic effects of fluoropyrimidines such as 5-FU by stabilising
the FdUMP/TS complex and enhancing the inhibition of DNA
synthesis (Tsai et al, 1990; Ardalan et al, 1998). It is combined
with UFT to further potentiate the effect of 5-FU on tumour cells
(Hoff et al, 1999b).
Two phase III studies in previously untreated patients
with mCRC compared a regimen of UFT 300mgm
–2day
–1 with
LV 75–90mg thrice daily for 28 days and repeated every 35 days
against the standard Mayo Clinic regimen of intravenous 5-FU 425
plus LV 20mgm
–2day
–1 for 5 days repeated every 28 (Douillard
et al, 2002) or 35 days (Carmichael et al, 2002). Patients receiving
UFT with LV experienced less diarrhoea and mucositis than those
who received 5-FU/LV and showed similar response rates, time to
progression (TTP) and median overall survival (OS).
The daily dose of UFT with LV is usually divided into three daily
doses (Pazdur et al, 1998). Despite this requirement for thrice daily
administration, UFT was preferred to bolus 5-FU by the majority
of patients, mainly due to convenience, in a quality-of-life (QoL)
study in the treatment of mCRC (Sizer et al, 2006). An UFT twice
daily dosing schedule, which would potentially be more convenient
and have a positive effect on patients’ QoL, has been shown to be
as well tolerated as thrice daily dosing (Etienne-Grimaldi et al,
2007). In this phase II pharmacokinetic study, 21 patients with
mCRC were randomised to receive UFT 300mgm
–2day
–1plus LV
90mgm
2day
–1 on days 1–28 of a 35-day cycle either twice or
thrice daily for the first cycle. Patients were then crossed over to
the other dose schedule for the second cycle. Twice daily dosing
resulted in a twofold increase in the fluorouracil and uracil AUC
values but was as well tolerated as thrice daily dosing, suggesting
that this more convenient schedule may improve the UFT
therapeutic index.
To evaluate the feasibility of a more convenient twice daily
schedule, we conducted a phase II study of UFT with LV
administered twice daily for 28 days, repeated every 35 days, for
the treatment of patients with mCRC. The total daily UFT dose
(300mgm
–2) was the same as that investigated in two phase III
studies with thrice daily dosing (Carmichael et al, 2002; Douillard
et al, 2002).
PATIENTS AND METHODS
Patients
This was a non-randomised, multicentre, open-label phase II
study. The eligibility criteria included age X18 years, histologically
confirmed and measurable metastatic colorectal adenocarcinoma,
Eastern Cooperative Oncology Group (ECOG) performance status
p2, life expectancy 412 weeks, adequate haematological, renal
and hepatic function and no prior treatment for metastatic disease.
Patients who had received prior adjuvant treatment must have
completed their adjuvant treatment at least 6 months before study
enrolment. All women had to have a negative pre-study serum or
urine pregnancy test, unless they were postmenopausal or had
been surgically sterilised. Any women of childbearing potential
had to practise adequate contraception during the study. All
manifestations of toxicity from previous therapy must have
returned to baseline levels.
Ineligibility criteria included prior treatment for metastatic
disease with the exception of radiotherapy to treat local sympto-
matic lesions, concomitant use of another investigational drug, a
history of brain metastases or carcinomatous meningitis, prior
exposure to oral fluoropyrimidines and a history of other cancers
with the exception of basal cell skin cancers, carcinoma in situ of
the cervix or curatively treated cancers that had not recurred for
more than 5 years. Patients with an active serious infection, an
underlying medical condition that would impair their ability to
receive the protocol treatment, dementia or significantly altered
mental status that would prohibit the understanding and provision
of informed consent and patients who were breast feeding were
also excluded. All participating institutions obtained institutional
review board (IRB) approval. All patients were informed of the
investigational nature of the study and signed an IRB-approved,
informed-consent document.
Treatment
Tegafur–uracil was administered as 100mg capsules and LV was
administered as 15mg tablets supplied by Bristol-Myers Squibb
(Wallingford, CT, USA). Patients received UFT 300mgm
–2day
–1
with LV 30mg per dose, twice a day divided into two daily doses
administered every 12h for 28 days. The total daily UFT dose
was rounded up or down to the nearest 100mg. Patients were
instructed not to consume any food for 1h before and 1h after the
study medication was taken.
The dose of UFT for each cycle was reduced by 50mgm
–2day
–1
if patients had adverse events of grade 2 or higher according to the
National Cancer Institute Common Toxicity Criteria scale, version
2.0 (Table 1). Reductions were based on the occurrence of a grade
2 or higher adverse event in two consecutive cycles. If the adverse
event was grade 3, UFT was withheld until the event returned to
baseline levels. No changes were made to the LV dose; however, if
UFT was withheld, LV was also withheld. Treatment could be
delayed for up to 2 weeks to allow for recovery from adverse
events. If doses were withheld because of adverse events, the days
that therapy was omitted were still counted as part of the 28-day
treatment cycle. If UFT was withheld for adverse events during a
treatment period and the adverse events resolved, the patient
resumed treatment at the same dose level that was used before the
dose was withheld.
Patient evaluation
All patients were evaluated with a complete medical history and
physical examination, including performance status, radiographic
imaging and laboratory tests. Patients were contacted weekly by
telephone to elicit information regarding adverse events and
compliance. Adverse events were assessed directly during the
scheduled office visit each cycle. Patients completed daily diaries
in which they recorded the time each dose of medication was taken
and all perceived adverse events.
Tumour response was evaluated every two cycles and continued
until disease progression. A complete response (CR) was defined
as the complete disappearance of all tumour lesions and normali-
sation of tumour markers. A partial response (PR) was defined as a
decrease of 450% in the sum of the products of the two largest
perpendicular diameters of all measurable lesions, with no lesions
progressing and no new lesions appearing. Stable disease (SD) was
defined as a lack of response, as defined above, in the absence of
any progressive disease (PD), which was defined as a 425%
increase in the size of any measurable or evaluable lesion, the
appearance of any new lesions or the occurrence of malignant
pleural effusion or ascites. Death secondary to malignant disease
was documented as PD. Objective responses were documented
Table 1 UFT dose levels
Dose level UFT (mgm
–2day
–1)
0 300
–1 250
–2 200
Twice daily UFT with LV in patients with mCRC
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swith a repeat measurement performed as close to 4 weeks from the
original assessment as feasible.
Treatment continued until disease progression, unacceptable
toxicity or withdrawal of consent. For patients who remained
progression free for 1 year, continuation of therapy was left to the
investigator’s discretion. Time to progression was calculated for
all patients from the date of beginning the study until the date that
PD or death was first reported. Data from patients whose disease
did not progress were censored at the last date they were known
to be alive. Patients who died of disease and for whom a date
of progression was not available were considered to have had
progressed on the day of death. For all patients, survival was
calculated from the date of beginning the study to the date of
death. Data from patients who did not die were censored at the
date they were last known to be alive.
Statistical methods
The primary end point of this study was to evaluate the TTP and
the proportion of patients who remained progression free at
6 months. Planned secondary end points included ORR, OS and
tolerability. On the basis of the results of the phase III UFT thrice
daily studies (Carmichael et al, 2002; Douillard et al, 2002), the
proportion of patients who would be progression free at 6 months
was estimated to be 30%. Assuming an exponential distribution of
TTP, this equates to a median TTP of 3.45 months and a per month
hazard rate of 0.201. The total sample size planned was 90 eligible
patients, which allowed for estimating the true hazard rate to
within 0.082 in that the 95% confidence interval (CI) would be
0.162–0.244 for an observed hazard rate of 0.201. In this design,
the twice daily UFT schedule would be considered non-inferior to
the thrice daily schedule if the TTP was 42.8 months (corres-
ponding to the upper confidence limit of 0.244 for the per month
hazard rate) with a one-sided test for non-inferiority at the
5% significance level. The maximum likelihood estimate was
used to calculate median TTP, although, as a secondary analysis,
the Kaplan–Meier estimate was also used to show the empirical
distributions of TTP and OS. All eligible patients were included in
these analyses.
RESULTS
A total of 98 patients were enrolled in this study and treated
between September 1999 and December 2001. Patient demo-
graphics are listed in Table 2. All patients received at least one dose
of UFT with LV and were evaluable for safety. Seven patients had a
protocol violation: one patient received adjuvant tegafur, one
patient had progressed within 6 months of receiving adjuvant
treatment, two patients had lesions smaller than the required
1.5cm and three patients had raised baseline levels of bilirubin or
liver enzyme levels. However, 97 patients were included in the
efficacy analysis. A total of 394 cycles were administered, with a
mean of four cycles per patient (range: 1–17). Seventy-one
patients (73%) discontinued treatment because of PD, six patients
(6%) refused further treatment, five patients (5%) were removed
from the study by the investigator, six patients (6%) were removed
from the study because of adverse events, six patients (6%) died
during the study, three patients (3%) were removed from the study
because of concurrent illness and one patient (1%) was removed
because he had a liver resection.
All patients experienced at least one adverse event, the most
common being asthenia (75% of patients), diarrhoea (66%) and
nausea (57%). Forty-three patients had at least one grade 3/4
treatment-related adverse event. The most frequent grade 3/4
adverse events considered to be treatment related were diarrhoea
(30% of patients), asthenia (12%), dehydration (9%), nausea (5%)
and vomiting (4%). Four patients (4%) had grade 3 anaemia and
seven (7%) had grade 3/4 hyperbilirubinaemia (six grade 3 and one
grade 4). Seven patients (7%) were removed from the study
because of adverse events (two with severe diarrhoea, two with
severe dehydration, one with severe fatigue and abdominal pain,
one with hyperbilirubinaemia and one with severe nausea and
vomiting). A total of 13 patients died either during the study or
within 30 days of last receiving study medication. Two deaths were
considered to be treatment related. The first was a 79-year-old
patient with severe diarrhoea followed by renal failure and
the second was an 82-year-old patient with severe diarrhoea
followed by sepsis. The presumed cause of death for all 13 cases is
listed in Table 3.
Table 4 summarises the tumour response for all patients
included in the study. Two patients (2%) had a CR and nine
patients (9%) had a PR (95% CI: 4.7–16.8). The ORR was 11%
(95% CI: 6.1–19.2%). Thirty-nine patients (40%) had SD (95%
CI: 30.3–50.1%) and 31 patients (32%) had PD (95% CI: 22.9–
41.7%). Seventeen patients (17%) were not evaluable for tumour
response because they did not complete two cycles of study
therapy or had no clear evidence of clinical progression; they
were, however, included in the denominator for calculating
response rate.
The median TTP was 3.8 months (95% CI: 3.11–4.65) and
the percentage of patients’ progression free at 6 months was
33% based on an exponential distribution. On the basis of
the secondary Kaplan–Meier analysis, the median TTP was
4.5 months and the proportion of patients progression-free at
6 months was 29%. Using the Cox proportional hazards regression
model, none of the following variables was found to be a
significant predictor of TTP: patient age, performance status,
primary disease location, prior adjuvant therapy and the interval
between adjuvant therapy and the diagnosis of metastatic disease.
Table 2 Baseline patient demographics
Characteristic
No. of patients
(n¼98) %
Median age, years (range) 64 (38–93)
Sex
Male 58 59
Female 40 41
Race
White 73 75
Black 12 12
Hispanic 7 7
Other 6 6
ECOG performance status
03 4 3 5
14 9 5 0
21 5 1 5
Prior therapy
Chemotherapy 24 25
Immunotherapy 1 1
Radiotherapy 13 13
Primary tumour site
Colon 81 83
Rectum 17 17
Metastatic site
Liver 81 83
Lung 29 30
Lymph nodes 21 21
Other 35 36
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12.8 months (95% CI: 9.6–15.8).
DISCUSSION
The rationale for this study was to evaluate whether the twice daily
schedule for the administration of UFT provided similar efficacy
and tolerability compared with the thrice daily schedule. We
estimated that the proportion of patients who would be progres-
sion free at 6 months would be 30%, which would equate to a
median TTP of 3.45 months. On the basis of the 97 eligible patients
in our study, 33% were progression-free at 6 months and the
median TTP was 3.8 months. The Kaplan–Meier estimator was
also used to show the empirical distribution of TTP as a secondary
analysis, showing that 29% of the patients were progression free at
6 months and the median TTP was approximately 4.5 months. The
median TTP for thrice daily UFT in the two phase III studies was
3.4 and 3.5 months, the ORR was 11 and 12% and median OS was
12.2 and 12.4 months (Carmichael et al, 2002; Douillard et al,
2002). The results of our study indicate that UFT with LV given as
a twice daily schedule for the treatment of patients with mCRC has
similar antitumour activity to that seen with the thrice daily
schedule in two phase III studies (Carmichael et al, 2002; Douillard
et al, 2002). The median TTP of 3.8 months in our study is non-
inferior to 3.4 and 3.5 months reported for the thrice daily
schedules in two phase III studies (Carmichael et al, 2002;
Douillard et al, 2002). In addition, the ORR and median OS for
the twice daily schedule were similar to those reported for the
thrice daily schedule.
As expected, grade 3/4 haematological events were uncommon
in our study and were limited to four patients (4%) with grade 3
anaemia. The most frequent grade 3/4 treatment-related non-
haematological adverse events were diarrhoea (30%) and asthenia
(12%). The tolerability profile of the twice daily schedule appears
to be similar to that reported for the thrice daily schedule in the
phase III clinical studies and the most common adverse events
with both schedules were gastrointestinal. The incidence of
grade 3/4 treatment-related diarrhoea and nausea/vomiting was
21 and 13%, respectively, with the thrice daily schedule
(Carmichael et al, 2002; Douillard et al, 2002) compared with 30
and 9%, respectively, with the twice daily schedule. No cases of
hand-foot syndrome were reported in one study (Carmichael et al,
2002), and in the other study (Douillard et al, 2002), only eight
patients (2%) had mild symptoms and no patients had severe
hand-foot syndrome. There was no significant hand-foot
syndrome in our study.
Although two patients (2%) died from severe diarrhoea in our
study, the overall treatment-related mortality for this schedule is
consistent with that seen with the use of other chemotherapy
regimens in mCRC (Rothenberg et al, 2001). A polymorphism in
CYP2A6, a cytochrome P450 enzyme reported to metabolise
tegafur to 5-FU, has been demonstrated in a recent report of one
patient treated with UFT who developed severe diarrhoea and fatal
sepsis (Bosch et al, 2007). It was hypothesised in this report that
altered metabolism due to this polymorphism resulted in increased
toxicity.
The efficacy of twice daily UFT with LV also appears to be
similar to that reported for twice daily capecitabine in two phase
III studies of first-line treatment for mCRC, with ORRs of 19
and 26%, median TTPs of 4.3 and 5.2 months, and median OS of
12.5 and 13.2 months (Hoff et al, 2001; Van Cutsem et al, 2001).
In conclusion, our results suggest that the twice daily schedule
of UFT with LV provides similar efficacy and tolerability to that of
the thrice daily schedule for the treatment of patients with mCRC
and is a reasonable alternative for patients who would benefit from
UFT with LV therapy.
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